Via the SME Instrument OmniSpirant Ltd will mature its stem cell exosome-packaged gene therapy with lung mucus
penetration properties which will be more effective (improved lung function, reversal of lung damage and superior CFTR
gene expression and function) and also be applicable to 100% of the CF global population. This approach, using a combined
patent pending exosome surface engineering for enhanced mucus penetration and cell transfection with a tailored vibrating
mesh nebulisation aerosol delivery method will provide a unique, potentially disruptive, therapeutic modality for CF and many
other lung diseases with high unmet medical need.
Our competitive advantage and Unique Selling Points lower current effectiveness barriers and make the OmniSpirant
exosome technology the only therapeutic delivery method that could provide a truly effective treatment for CF, thus
improving both survival rates the quality of life of CF suffers. Importantly, the quality of life for CF patients will increase to
point where they are able to work. The OmniSpirant system will, over time, be regarded as an essential weapon in the
armoury of health systems in the battle against other serious respiratory conditions affecting major patient populations such
as lung cancer and COPD, globally.
The overall objective of our feasibility study is to demonstrate the potential value of the combined gene therapy system
maturation based on a comprehensive analysis of the business concept in terms of technical, commercial and financial
viability. The outcome of the study will be a full Business Plan that will feed into a Phase 2 project.
Field of science
- /medical and health sciences/medical biotechnology/cells technologies/stem cells
- /social sciences/economics and business
- /medical and health sciences/medical biotechnology/genetic engineering/gene therapy
- /medical and health sciences/clinical medicine/oncology/cancer
Call for proposal
See other projects for this call